| 1. |
|
|
| 2. |
- Jakobsson, P, et al.
(författare)
-
A mean redshift of 2.8 for Swift gamma-ray bursts
- 2006
-
Ingår i: Astronomy & Astrophysics. - : EDP Sciences. - 0004-6361 .- 1432-0746. ; 447:3, s. 897-903
-
Tidskriftsartikel (refereegranskat)abstract
- The exceptionally high luminosities of gamma-ray bursts (GRBs), gradually emerging as extremely useful probes of star formation, make them promising tools for exploration of the high-redshift Universe. Here we present a carefully selected sample of Swift GRBs, intended to estimate in an unbiased way the GRB mean redshift (z(mean)), constraints on the fraction of high-redshift bursts and an upper limit on the fraction of heavily obscured afterglows. We find that z(mean) = 2.8 and that at least 7% of GRBs originate at z > 5. In addition, consistent with pre-Swift observations, at most 20% of afterglows can be heavily obscured. The redshift distribution of the sample is qualitatively consistent with models where the GRB rate is proportional to the star formation rate in the Universe. We also report optical, near-infrared and X-ray observations of the afterglow of GRB 050814, which was seen to exhibit very red optical colours. By modelling its spectral energy distribution we find that z = 5.3 +/- 0.3. The high mean redshift of GRBs and their wide redshift range clearly demonstrates their suitability as efficient probes of galaxies and the intergalactic medium over a significant fraction of the history of the Universe.
|
|
| 3. |
|
|
| 4. |
|
|
| 5. |
- Landgren, O, et al.
(författare)
-
Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation
- 2009
-
Ingår i: Blood. - : American Society of Hematology. - 1528-0020 .- 0006-4971. ; 113:20, s. 4992-5001
-
Tidskriftsartikel (refereegranskat)abstract
- We evaluated 26 901 patients who underwent allogeneic hematopoietic cell transplantation (HCT) at 271 centers worldwide to define patterns of posttransplantation lymphoproliferative disorders (PTLDs). PTLDs developed in 127 recipients, with 105 (83%) cases occurring within 1 year after transplantation. In multivariate analyses, we confirmed that PTLD risks were strongly associated (P < .001) with T-cell depletion of the donor marrow, antithymocyte globulin (ATG) use, and unrelated or HLA-mismatched grafts (URD/HLA mismatch). Significant associations were also confirmed for acute and chronic graft-versus-host disease. The increased risk associated with URD/HLA-mismatched donors (RR = 3.8) was limited to patients with T-cell depletion or ATG use (P = .004). New findings were elevated risks for age 50 years or older at transplantation (RR = 5.1; P < .001) and second transplantation (RR = 3.5; P < .001). Lower risks were found for T-cell depletion methods that remove both T and B cells (alemtuzumab and elutriation, RR = 3.1; P = .025) compared with other methods (RR = 9.4; P = .005 for difference). The cumulative incidence of PTLDs was low (0.2%) among 21 686 patients with no major risk factors, but increased to 1.1%, 3.6%, and 8.1% with 1, 2, and more than 3 major risk factors, respectively. Our findings identify subgroups of patients who underwent allogeneic HCT at elevated risk of PTLDs for whom prospective monitoring of Epstein-Barr virus activation and early treatment intervention may be particularly beneficial.
|
|
| 6. |
|
|
| 7. |
|
|
